Edition:
United States

Aeglea Bio Therapeutics Inc (AGLE.OQ)

AGLE.OQ on NASDAQ Stock Exchange Global Market

6.35USD
23 Feb 2018
Change (% chg)

$-0.01 (-0.16%)
Prev Close
$6.36
Open
$6.40
Day's High
$6.40
Day's Low
$6.02
Volume
12,700
Avg. Vol
14,856
52-wk High
$8.14
52-wk Low
$2.81

Chart for

About

Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company's product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102,... (more)

Overall

Beta: --
Market Cap(Mil.): $104.69
Shares Outstanding(Mil.): 16.64
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-Aeglea Biotherapeutics announces clinical collaboration with Merck

* Aeglea Biotherapeutics announces clinical collaboration with Merck to evaluate the combination of Aeglea’S AEB1102 (pegzilarginase) with Merck's Keytruda® (pembrolizumab) for the treatment of small cell lung cancer

Oct 16 2017

Earnings vs. Estimates